Chen: Male, born in 1962, American nationality, doctor of organic chemistry, founded Tonghe Capital on 20 12, and served as the managing partner, with 20 years of experience. 2065438+In May 2007, two teams, Tonghe Capital and Yucheng Capital, merged to form a new fund focusing on medical and health fields, with Dr. Chen as CEO of Tonghe Yucheng. Prior to this, Dr. Chen was a partner of Fidelity Asia Growth Fund and a managing partner of Avida Investment Company. Since 2005, Dr. Chen has led a number of investments in life sciences in China, including CITIC Medicine, Biology, Hualing Medicine, Cinda Biology, Tian Yan Pharmaceutical, Dannuo Medical, mcgrady Peak, Medicine, Yikang Gene, Shanghai Huazhou, Kangtai Bio and Neusoft Medical. Mr. Chen worked for McKinsey & Company in Europe and Ernst & Young Company in the United States. From 1993 to 1997, Mr. Chen worked in Schering-Plough Pharmaceutical Company, New Jersey, USA. He is a member of the "Vytorin"/"Zetia" drug invention team, and the annual sales of this drug has exceeded billions of dollars. Mr. Chen holds a postdoctoral degree from the Massachusetts Institute of Technology, a doctorate (highest honor) from the University of Leuven and a bachelor's degree from Peking University. Mr. Chen holds six American invention patents and co-authored the famous Ernst & Young Biotechnology YearbookNo. 14 andNo. 15. He is currently a director of the company.